NOTCH3 and hepatocellular carcinoma: This is in line with previous data, were Notch3 overexpressing HCC cells were shown to have increased aldehyde dehydrogenase activity (Zhang et al., 2015[42]), characteristic for LPCs (Dolle et al., 2012[9]) and inhibition was shown to overcome therapy resistance in HCC cells, increasing sorafenib toxicity (Giovannini et al., 2013[12]).